

### 5-Year Outcomes Of The ICEBERG Study Of The Gore IBD (IBE Device) For Revascularizing The Hypogastric Artery With Aortoiliac Aneurysms: Advantages And Limitations

Michel MPJ Reijnen, MD, PhD  
 Department of Vascular Surgery, Rijnstate, Arnhem  
 MultiModality Medical Imaging Group, University of Twente, Enschede  
 The Netherlands

### Disclosures

- Consultancy and/or Research Funding:
  - WL Gore and Associates
  - Terumo Aortic
  - Medtronic
  - Artivion
- The IceBERG study was funded by an unrestricted grant from WL Gore and associates

### Society guidelines

**The Society for Vascular Surgery (SVS):**


- Preservation of flow to at least one internal iliac artery.
- Level of recommendation: 1 (Strong)
- Quality of evidence: A (High)

**European Society for Vascular Surgery (ESVS):**

- The availability of iliac side branch stent grafts now allows preservation of IIA flow in most cases.
- Level of recommendation: 1
- Quality of evidence: B


**Japanese Society for Vascular Surgery (JCS/JSCS/JATS/JSVS):**

- We recommend preservation of flow to at least on internal iliac artery.
- Level of recommendation: 2a
- Quality of evidence: B



### Iliac Branched Devices Gore Excluder Iliac Branch Endoprosthesis

- Introduced in EU in November 2013
- 16 Fr introducer sheath
- Intended to be used in combination with the Excluder device
- Self-expanding iliac component based on the Excluder platform
- Option for repositioning



### ICEBERG registry

- Prospective multi-center, real-world registry
- 100 included patients
- Follow-up schedule

**Inclusion criteria**

- Age 18 years or older
- Written informed consent
- Elective procedure
- Indication for aorto-iliac endovascular stent graft repair

**Exclusion criteria**

- Aortic diameter > 5.5 cm
- Aortic aneurysm in CIA or hypogastric arteries than the Excluder® Iliac branch Endoprosthesis
- Bleeding disorder
- Pregnancy
- Concomitant aneurysm
- Previous EVAR

van der Ween D, et al. Eur J Vasc Endovasc Surg. 2021 Aug;65(2):177-183

### Iceberg registry Baseline characteristics

|                          |            |                       |          |
|--------------------------|------------|-----------------------|----------|
| Age (years)              | 69.6 ± 8.4 | Buttock claudication  | 6 (6%)   |
| Male gender              | 97 (97%)   | Erectile dysfunction  | 14 (15%) |
| BMI (kg/m <sup>2</sup> ) | 26.9 ± 4.1 | AAA present (>30 mm)* | 75 (75%) |
| Hypertension             | 66 (66%)   | CIA aneurysm          | 95 (95%) |
| Diabetes mellitus        | 11 (11%)   | Left                  | 17 (17%) |
| Hyperlipidemia           | 60 (60%)   | Right                 | 33 (33%) |
| Current smoking          | 27 (27%)   | bilateral             | 45 (45%) |
| Cardiac disease          | 27 (27%)   | IIA aneurysm          | 17 (17%) |
| Renal impairment         | 14 (14%)   | Concomitant aneurysm  | 18 (18%) |
| Pulmonary disease        | 26 (26%)   | Previous EVAR         | 4 (4%)   |

\* AAA with diameter above the threshold for treatment n=32

van der Ween D, et al. Eur J Vasc Endovasc Surg. 2021 Aug;65(2):177-183

### Iceberg registry Procedural data

- Isolated IBE in 7 cases and bilateral IBE in 22 cases
- Procedural time 151 min (IQR 117-193 min)
- Contrast 130 mL (IQR 100-180 mL)
- Landing in main IIA branch in 85/100 patients
- Contralateral IIA;
  - Patent and preserved 60%
  - Second IBE 22%
  - Patent and overstented 13%
  - Not patent before procedure 5%

van der Veen D, et al. Eur J Vasc Endovasc Surg. 2021 Aug;48(2):177-183

### Key one-year outcomes IceBERG, IDE, GREAT & GALICIAN trials

|                       | Patients | Technical success | Bilateral IBE | Contralateral embolization | Procedural mortality | Re-interventions | Hypogastric patency |
|-----------------------|----------|-------------------|---------------|----------------------------|----------------------|------------------|---------------------|
| <b>IceBERG trial</b>  | 100      | 99%               | 20            | 13                         | 0%                   | 3%               | 91.3%               |
| <b>GREAT registry</b> | 92       | 98,1%             | 13            | N.A.                       | 0%                   | 5,4%             | 100%                |
| <b>IDE trial</b>      | 99       | 95,2%             | 4             | 26                         | 0%                   | 5,1%             | 93,6%               |
| <b>GALICIAN trial</b> | 81       | 99%               | 24            | 9                          | 0%                   | 6,2%             | 98,1%               |

### Iceberg registry update 5-year technical outcomes

**At 5-year follow-up;**

- Freedom from type Ia endoleak 97.9%
- Freedom from type Ib endoleak 97.9%
- Freedom from type II endoleak 64.4%
- Freedom from type III endoleak 97.7%

| Endoleak type                         | No. at risk | Survival % |
|---------------------------------------|-------------|------------|
| <b>Freedom from type Ia endoleak</b>  | 100         | 97.9       |
| <b>Freedom from type Ib endoleak</b>  | 100         | 97.9       |
| <b>Freedom from type II endoleak</b>  | 100         | 64.4       |
| <b>Freedom from type III endoleak</b> | 100         | 97.7       |

Interim analysis, subjected to changes

### Iceberg registry update 5-year technical outcomes

**Overall 5-year primary patency of iliac component 84.0%**

- Overall 85.0%
- Outside IFU 68.6%

**Primary patency for patients inside and outside the anatomical requirements of the IFU was 85.0% and 68.6% (p=0.270)**

Interim analysis, subjected to changes

### Iceberg registry update 5-year technical outcomes

**At 5-year follow-up;**

- Freedom from all-cause mortality 82.9%
- Freedom from AAA rupture 95.8%
- Freedom from AAA-related mortality 96.0%
- Freedom from secondary interventions 92.2%

**Aortic diameter** p=0.001

**CIA diameter** p<0.001



Interim analysis, subjected to changes

### Iceberg registry update 5-year technical outcomes

**Eight reinterventions through 5-year follow-up of which 5/8 endovascular:**

- Embolization of type II EL n=1
- Extension of hypogastric branch because loss of seal n=2
- Relining type III EL n=2
  - One for a ruptured aneurysm
- Femoro-femoral bypass for EIA occlusion n=1
- External to internal iliac artery bypass n=1
- Explantation of EVAR device, with preservation of IBE for sac enlargement n=1

Interim analysis, subjected to changes



- ### Summary
- IIA preservation is indicated when treating iliac artery aneurysms, especially in young patients
  - The IceBERG study shows favorable 5-year results of the Gore Excluder Iliac Branch Endoprosthesis, both considering technical and clinical outcome parameters
  - Erectile dysfunction is prevalent, underestimated and in the early phase related to contralateral occlusions

### Acknowledgements

- Daphne van der Veen
- Suzanne Holewijn
- Raffaello Bellosta
- Steven van Sterkenburg
- Jan Heyligers
- Ilaria Ficarelli
- Francisco Gómez Palonés
- Nicola Mangialardi
- Nilo Mosquera
- Andrew Holden
- The ICEBERG Study collaboration

Rijnstate UNIVERSITY OF TWENTE

### 5-Year Outcomes Of The ICEBERG Study Of The Gore IBD (IBE Device) For Revascularizing The Hypogastric Artery With Aortoiliac Aneurysms: Advantages And Limitations

Michel MPJ Reijnen, MD, PhD  
Department of Vascular Surgery, Rijnstate, Arnhem  
MultiModality Medical Imaging Group, University of Twente, Enschede  
The Netherlands